# IL-21 as a Therapeutic to Reduce Immune Activation and Normalize Microbial Dysbiosis in SIV-Infected ART-Suppressed Infant Macaques

> **NIH NIH F31** · EMORY UNIVERSITY · 2021 · $46,036

## Abstract

PROJECT SUMMARY
Globally, 1.8 million children are living with HIV-1 and over half of the ~180,000 new infections annually occur
postnatally through breast milk transmission. While antiretroviral therapy (ART) has improved disease outcome
and reduced transmission, residual immune activation persists during ART and interruption of ART leads to
rapid viral rebound due to the latent viral reservoir. Interventions to delay or prevent viral rebound in the
absence of ART would be highly beneficial to the pediatric population who must remain on ART throughout
their lifespan. In adults, microbial dysbiosis thought to drive disease progression is evident within the first few
weeks of HIV-1 infection and is not restored through ART administration. The effect of HIV infection on the
developing microbiome and its role in disease progression of infants is not well defined. The objective of this
proposal is to provide insight into the microbiome composition and function during SIV infection and investigate
the effect of IL-21 as a therapeutic to reduce microbial dysbiosis in SIV-infected ART-suppressed infant rhesus
macaques (RMs). IL-21 drives Th17 differentiation, a population of immune cells critical to mucosal immune
homeostasis and intestinal epithelial barrier function that are preferentially depleted in early HIV/SIV infection.
IL-21 recently showed promising results in adult RMs and is predicted to favorably impact the immune
dysfunction induced by HIV-1 infection in infants. The scientific premise is that our novel model of postnatal
oral SIV infection and suppressive ART in infant RMs will allow us to generate key data on microbiome
composition and function and the impact of a potential therapeutic, IL-21. The central hypothesis is that by
restoring Th17 CD4+ T cells through administration of exogenous IL-21, we will reverse microbial dysbiosis
that occurs following SIV infection resulting in reduced immune activation and a reduction in both viral
reservoirs on ART and set point viremia after ART interruption. We will test this hypothesis in the following
Specific Aims: 1) To determine the impact of SIV infection and ART suppression on microbiome development
in infant RMs; 2) To determine the impact of IL-21 on the microbiome in SIV-infected ART-suppressed infant
RMs. A key feature of this proposal is the use of our novel, highly relevant animal model to perform controlled
studies of an innovative immune-based approach that is directly translatable to future clinical trials. We expect
that the findings from this proposal will critically inform our understanding of HIV-1 pathogenesis and
therapeutic approaches in the pediatric population.

## Key facts

- **NIH application ID:** 10102120
- **Project number:** 5F31HD100265-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Katherine M Bricker
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $46,036
- **Award type:** 5
- **Project period:** 2020-02-15 → 2022-02-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10102120

## Citation

> US National Institutes of Health, RePORTER application 10102120, IL-21 as a Therapeutic to Reduce Immune Activation and Normalize Microbial Dysbiosis in SIV-Infected ART-Suppressed Infant Macaques (5F31HD100265-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10102120. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*